A Phase 3 interventional study of CHF 5993 100/6/12.5 µg and 160 µg budesonide + 4.5 µg formoterol fumarate in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 64 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 13th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2016, is one of 16 in phase 3, and was the 38th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:
Chiesi Farmaceutica Ltda. · Sites in Brazil
Ages 40+
Chiesi Hungary Ltd. · Sites in Hungary
Ages 18+
Chiesi SAS · Sites in France
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 40+
Chiesi UK
Ages 55–75
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 19 · Phase 3 16 · Phase 4 3
First in 2004; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 708 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 65 across the 59 interventional studies, 661 across the 9 observational. Of the 62 that completed or were terminated, 7 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
2 of the studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05652439Chiesi Farmaceutici S.p.A.PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) | 2027-03 |
| NCT07406048Chiesi Farmaceutica Ltda.Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective
Secondary Objectives
Key secondary objective:
Other secondary objectives:
This was a phase III, 24-week, randomised, double-blind, double-dummy, Multinational (China, South Korea, Taiwan), Multicentre, 2-arm parallel-group, active-controlled study in patients with COPD.
The study was designed to demonstrate the superiority of CHF 5993 pMDI over budesonide/formoterol in terms of pulmonary function (change from baseline in pre-dose morning FEV1 and 2-hour post-dose morning FEV1 at Week 24), both in the overall study population and in the Chinese population. The study lasted approximately 27 weeks for each patient, and a total of 7 clinic visits (Visit [V] 0 to V6) were performed during the study, plus a follow-up phone call.
A pre-screening visit (Visit [V] 0) was planned to occur no more than 7 days before a screening visit (V1, Week -2), followed by a 2-week open-label run-in period on Symbicort® Turbuhaler® (budesonide/formoterol fumarate [FF] 160/4.5 μg per inhalation), 2 inhalations twice daily (BID) (total daily dose: 640/18 μg budesonide/FF). The 2-week run-in period was deemed sufficient in order to 'standardise' the target population on the same treatment (Symbicort® Turbuhaler® [budesonide/FF 160/4.5 μg per inhalation]) prior to randomisation to study treatments, without leading to a deterioration in the disease.
At the randomisation visit (V2, Week 0), patients were randomised in a 1:1 ratio to one of the following two treatments for 24 weeks:
The length of the treatment period (24 weeks) was considered as adequate to evaluate the long-term efficacy and safety of CHF 5993 pMDI 100/6/12.5 μg versus (vs) budesonide/formoterol in terms of lung function.
Salbutamol was purchased locally by the vendor and used as rescue medication on an as-needed basis during both the run-in and treatment periods.
Four subsequent visits were performed after 4 weeks (V3), 12 weeks (V4), 18 weeks (V5), and 24 weeks (V6) of treatment. A time window of ±3 days was allowed for the visit dates from V2 to V6. An early termination (ET) visit was to be performed in the event of premature study discontinuation, during which all efforts were made to perform the assessments that should have been done at Week 24 (V6). A safety follow-up phone call was scheduled with the patient 7-10 days after last study treatment intake or ET visit in order to check the status of any unresolved adverse events (AEs) at the last visit.
Following the outbreak of the coronavirus disease-19 (COVID-19) pandemic the conduct of the study was adapted to ensure the safety of the patients and staff as well as the study continuity (see Section 9.8.1.2). Sites were instructed that patient retention was privileged with continuity of investigational drug supply. As emergency measures, it was authorised to postpone planned patients' visits or conduct remote visits and have the investigational product delivered to patients' home. Specific process for performing and reporting of Remote Visits was followed to cover all remote visits conducted during the period of the COVID-19 outbreak.
Study assessments
During the study, from screening (V1, Week -2) to end of treatment (V6, Week 24):
The final analysis included a total of 1053 screened patients and 708 randomised patients (353 patients received CHF 5993 pMDI and 355 patients received budesonide/formoterol). This included 826 patients screened in China of whom 578 patients were randomised to one of two treatments: CHF 5993 pMDI (288 patients) and budesonide/formoterol (290 patients). Overall there were 612 evaluable patients, including 506 evaluable patients in China. Of the 708 randomised patients, 706 patients were included in the Intention-to-treat (ITT) population (CHF 5993 pMDI: n=351; budesonide/formoterol: n=355).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients had to meet all of the following inclusion criteria to be eligible for enrolment into the study:
Patients under therapy for at least 2 months prior to screening with either:
All inclusion criteria were checked at screening (V1, Week -2). If criterion #4 was not met at V1, the test could be repeated once before the randomisation visit (V2, Week 0). Inclusion criteria #7 and #8 were to be re-checked at the randomisation visit (V2, Week 0).
Exclusion Criteria:
If a patient met any of the following criteria, he/she was not enrolled into the study:
Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) UNLESS are willing to use one or more of the following reliable methods of :
Any women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilised (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) could have been enrolled in the study;
Patients requiring use of the following medications:
Patients with atrial fibrillation (AF):
All exclusion criteria except for criterion #4 were checked at screening (V1, Week -2).
The following exclusion criteria were to be re-checked at the randomisation visit (V2, Week 0): #1,
#4, #5, #6, #7, #10, #11, #12, #17, and #20. For patients in South Korea (only), the following were added to the South Korea-specific protocol (version 3.0):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg (BDP/FF/GB), 2 inhalations bid, for a total daily dose of 400/24/50 μg BDP/FF/GB respectively, administered via pMDI. If patients were used to inhaling their pMDI COPD medications with a spacer device, the AeroChamber PlusTM was used with the study pMDI treatments, dispensed to the patients at V2 (Week 0) and V4 (Week 12).
Drug: CHF 5993 100/6/12.5 µg
Fixed combination of 160 µg budesonide (BUD) + 4.5 µg formoterol fumarate (FF), 2 inhalations a day, for a total daily dose of 640/18 μg BUD/FF respectively, administered via dry powder inhaler (DPI).
Drug: 160 µg budesonide + 4.5 µg formoterol fumarate
Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
Also known as: BDP/FF/GB, beclometasone dipropionate / formoterol fumarate / glycopyrronium bromide
Drug pages: Budesonide · Formoterol
Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
Also known as: BUD/FF, Budesonide / formoterol fumarate
Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
Time frame: Week 24 (Visit 6)
Change From Baseline in 2-hour Post-dose FEV1 at Week 24
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
Time frame: Week 24 (Visit 6)
Change From Baseline in Pre-dose Morning FEV1 at All the Other Clinic Visits
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
Time frame: Pre-dose morning at week 4 (visit 3), week 12 (visit 4), week 18 (visit 5), week 24 (visit 6)
Change From Baseline at 2-hour Post-dose FEV1 at All the Clinic Visits
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
Time frame: 2-hour post-dose morning at week 0 (V2), week 4 (V3), week 12 (V4), week 18 (V5), week 24 (V6)
Change From Baseline in Pre-dose FEV1 ≥ 100 mL at Week 24
FEV1 response is defined as a change from baseline in pre-dose morning FEV1 ≥ 100 mL. If the change from baseline is \< 100 mL the patient is classified as a non-responder in terms of FEV1. Patients with missing pre-dose morning FEV1 value at the relevant time points were also be classified as non-responders. The number and percentage of FEV1 responders/non-responders (distinguishing also the two categories of non-responders: with a change from baseline actually \< 100 mL or with missing data) at Visit 6 are presented by treatment group.
Time frame: Week 24 (V6)
Changes From Pre-Dose to the 2-Hour Post-Dose Value of FEV1 at Each Visit From Visit 3 Onwards
The changes from pre-dose to the 2-hour post-dose morning FEV1 at each clinic visit from V3 onwards are presented by treatment in the ITT population. Please note that the adjusted mean is reported with its 95%IC.
Time frame: Week 4 (V3), week 12 (V4), week 18 (V5), week 24 (V6)
Adjusted Rate Per Patient Per Year of Moderate or Severe COPD Exacerbations Over 24 Weeks of Treatment
Moderate or Severe COPD exacerbations during the randomised treatment period derived from the COPD exacerbations (E) eCRF form were considered for the analysis. Only E with start date ≥ date of start of randomised treatment period and ≤ date of end of randomised treatment period were considered. Please note that in the analysis, two COPD E were considered as a single episode if the 2nd E started less than 10 days: * after the end of the systemic corticosteroids and/or antibiotics intake for the previous E; * after the onset of the previous E. In case of at least 1 E occurring before the randomisation and at least 1 E occurring after randomisation satisfied the rules above to be considered as single episode, then the resulting event was considered as occurring before the randomisation (i.e. it wasn't considered in the analyses of moderate or severe Es). Adjusted exacerbation rate per patient per year was reported (= number) with its 95% IC.
Time frame: Over the 24-week treatment period
Time to First Moderate or Severe COPD Exacerbation Over 24 Weeks of Treatment
In patients with at least one moderate/severe COPD exacerbation, time to first moderate/severe COPD exacerbation was calculated as the time in weeks between the start date of randomised treatment period and the date at which the first COPD exacerbation occurs. Time to first moderate/severe COPD exacerbation (weeks) = (date of start of first moderate/severe COPD exacerbation - date of start of randomised treatment period)/7. Please note that the Rows don't represent mutually exclusive and exhaustive categories of the overall number of participants analyzed (N=351 for CHF 5993 and N=355 for Symbicort Turbuhaler). The number of exacerbation-free patients at the beginning of each study period is reported for each row (not the number of participants analyzed), with the relative cumulative number of patients with first moderate/severe exacerbation at the end of each study period (unit of measure).
Time frame: From baseline to week 24 (EOT)
Change From Baseline in Pre-Dose Morning Forced Vital Capacity (FVC) at All Clinic Visits
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Baseline in Pre-Dose Morning Forced Vital Capacity (FVC) at all clinic visits are presented by treatment in the ITT population. Please note that adjusted mean was reported with its 95%IC.
Time frame: Pre-dose morning, week 4 (V3), week 12 (V4), week 18 (V5), week 24 (V6)
Change From Baseline in 2-Hour Post-Dose Morning FVC at All Clinic Visits
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Baseline in 2-hour post-dose Forced Vital Capacity (FVC) at all clinic visits are presented by treatment in the ITT population. Please note that adjusted mean is reported with its 95%IC.
Time frame: 2-hour post dose, week 4 (V3), week 12 (V4), week 18 (V5), week 24 (V6)
Change From Pre-Dose to the 2-Hour Post-Dose Value of FVC at Each Visit From Visit 3 Onwards
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Pre-Dose to the 2-Hour Post-Dose Value of Forced Vital Capacity (FVC) at all clinic visits from V3 onwards are presented by treatment in the ITT population. Please note that adjusted mean is reported with its 95%IC.
Time frame: From Pre-Dose to the 2-Hour Post-Dose at week 4 (V3), week 12 (V4), week 18 (V5) and week 24 (V6)
Pre-Dose FEV1/FVC at All Clinic Visits
The FEV1/FVC ratio, also called modified Tiffeneau-Pinelli index, is a calculated ratio used in the diagnosis of obstructive and restrictive lung disease. The FEV1/FVC ratio is used to determine if the pattern is obstructive, restrictive, or normal. Chronic airflow limitation can be generally defined as fixed ratio of forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) \< 0.70 after bronchodilation. So the lower the value, the worse the outcome and the pattern. Pre-dose FEV1/FVC at each visit was summarised by treatment group using descriptive statistics.
Time frame: Pre-dose at baseline (V1), week 0 (V2), week 4 (V3), week 12 (V4), week 18 (V5), week 24 (V6)
Change From Baseline in Pre-dose Morning Forced Expiratory Flow Measured Between 25% and 75% of a Forced Vital Capacity (FEF25-75%) at All Clinic Visits
FEF25-75% is defined as "forced expiratory flow over the middle one-half of the FVC; the average flow from the point at which 25% of the FVC has been exhaled to the point at which 75% of the FVC has been exhaled." A reduced FEF25-75% is thought to be a marker of small airway obstruction. Hence, the lower the parameter, the worse the status of airways. Among the various measurements collected during conventional spirometry, forced expiratory flow at 25% and 75% of the pulmonary volume (FEF25-75) measures the average flow rates of medium-to-small airways during the forced vital capacity (FVC) segment to testing and presents the status of those airways in patients. The changes from baseline in pre-dose morning FEF25-75% at baseline and at all subsequent clinic visits are presented by treatment in the ITT population. Please note: adjusted mean is reported with its 95%IC.
Time frame: Pre-dose morning at week 4 (V3), week 12 (V4), week 18 (V5) and week 24 (V6)
Change From Baseline in Pre-dose Morning Inspiratory Capacity (IC) at All Clinic Visits
IC is the maximum volume of air that can be inspired following a normal, quiet expiration and is equal to tidal volume + inspiratory reserve volume. In airflow obstruction, hyperinflation of the lung and chest wall during tidal breathing (and during exercise) increases the work of breathing and contributes to the sensation of dyspnoea. The lower the volume, the worse the outcome and, consequently, the impairment. Please note that adjusted mean is reported with its 95%IC.
Time frame: Pre-dose morning at week 4 (V3), week 12 (V4), week 18 (V5) and week 24 (V6)
Change From Baseline in the Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 12 and Week 24
The SGRQ measures health impairment in patients with COPD. It is in two parts: Part I produces the Symptoms score, Part 2 the Activity and Impacts scores. Scaling of items * Section I (Symptoms): 5-point Likert * Sections II (Activity) and III (Impacts): Dichotomous (yes/no) Total score=(Summed weights from positive items in the SGRQ / Sum of weights for all items in the SGRQ) x 100. Lower the scores, better the health. Each item is "weighted" empirically. Scores range from 0 to 100, higher scores mean poor health. Part 1(Q 1-8) covers the patients' recollection of their symptoms over a preceding period that may range 1 month to 1 year. Part 2 (Q 9-16) addresses patients' current state. Activity score just measures disturbances to patients daily physical activity. Impacts score covers a wide range of disturbances of psycho-social function. Please note: adjusted mean is reported with its 95%IC.
Time frame: At weeks 12 and 24
Change From Baseline in the Number of Patients With SGRQ Total Score ≤ -4 (Defined as "Responders") at Week 24
The percentage of patients classified as SGRQ total score responders (i.e. change from baseline in total score ≤ -4) at Week 24 was reported. SGRQ response = Change from baseline in total score ≤ -4; SGRQ non-response = Change from baseline in total score \> -4 or missing data.
Time frame: At week 24
Changes From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) at All Clinical Visits
The COPD assessment test (CAT) is a self-administered questionnaire assessing globally the impact of COPD (cough, sputum, dysnea, chest tighteness) on health status. It's a simple, eight-item/question, health status instrument for patients with COPD to define the level of its impact on daily life. Each item can score from 0 (best outcome) to 5 (worst outcome). Hence, CAT total score, which is the sum of the single items' scores, ranges from 0 to 40. Higher scores denote a more severe impact of COPD on a patient's life. No target score represents the best achievable outcome. Please note that adjusted mean is reported with its 95%IC.
Time frame: At week 4 (V3), week 12 (V4), week 18 (V5) and week 24 (V6)
Change From Baseline to Each Inter-Visit Period and to the Entire Randomised Treatment Period in the Percentage of Days Without Intake of Rescue Medication
The percentage (%) of days without intake of rescue medications was evaluated on the basis of the infos recorded daily by each patient. The % of days in the run-in period was calculated as follows: % of days without rescue medication = (Number of days without rescue medication during the run-in period / Number of days with consistent data recorded during this period)\*100. The % of days in each inter-visit period during the randomised treatment period was calculated as follows: • % of days without rescue medication = (Number of days without rescue medication during the inter-visit period / Number of days with consistent data recorded during this period)\*100. The % of days in the entire randomised treatment period was calculated as follows: • % of days without rescue medication = (Number of days without rescue medication during the randomised treatment period / Number of days with consistent data recorded during this period)\*100.
Time frame: Weeks 1-4 (V2-V3); Weeks 5-12 (V3-V4); Weeks 13-18 (V4-V5); Weeks 19-24 (V5-V6); Weeks 1-24 (randomised treatment period)
Change From Baseline to Each Inter-Visit Period and to the Entire Treatment Period in the Average Use of Rescue Medication (Number of Puffs/Day)
The average use of rescue medication is expressed in "puffs/day". Data on each interval indicated in the timeframe and over the 24-week of the randomised treatment period is presented.
Time frame: Weeks 1-4 (V2-V3); Weeks 5-12 (V3-V4); Weeks 13-18 (V4-V5); Weeks 19-24 (V5-V6); Weeks 1-24 (randomised treatment period)
EQ-5D-3L Index at All Clinic Visits
The EQ-5D-3L (euro quality of life) consists of the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system comprises 5 dimensions: * mobility * self-care * usual activities * pain/discomfort * anxiety /depression. Each dimension has 3 levels: no problems, some problems, extreme problems. A unique health state is defined by combining 1 level from each of the 5 dimensions. There are 243 possible health states/sequences defined in this way. Each state is referred to in terms of a 5-digit code (for example 11223). The 243 theoretical possible sequences can then be mapped to an index value to provide a summary across all dimensions. For the calculation of the index value, the Time Trade-Off method was used. The index can range from 1 (full health) to 0 (worst health).
Time frame: At week 0 (V2), week 12 (V4) and week 24 (V6)
EQ-5D-3L VAS Scores at All Clinic Visits
The EQ-5D-3L (euro quality of life) consists of the EQ-5D descriptive system and the EQ VAS. The EQ VAS records the patient's self-rated health on a vertical, visual analogue scale where the endpoints are 'Worst imaginable health state' (0) and 'Best imaginable health state' (100).
Time frame: At week 0 (V2), week 12 (V4) and week 24 (V6)
Total Number of Hospital Admissions Due to COPD and to Other Causes
This health-economic outcome is expressed by the number of Hospital Admissions due to COPD and to Other Causes overall.
Time frame: From baseline to week 24 (V6)
Total Number of Oxygen Therapy Use Due to COPD
This health-economic outcome is expressed by the number of oxygen therapy use due to COPD.
Time frame: From baseline to week 24 (V6)
Total Number of Unplanned Diagnostic or Instrumental Tests Performed Due to COPD
This health-economic outcome is expressed by the number of Diagnostic or Instrumental tests performed due to COPD.
Time frame: From baseline to week 24 (V6)
Number of Adverse Events (AEs) and Adverse Drug Reactions (ADRs)
AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.
Time frame: From baseline to week 24 (V6)
A total of 1053 patients were screened, including 826 patients from China, 177 patients from South Korea, and 50 patients from Taiwan. Overall, 345 patients were screen failures.
| Milestone | CHF 5993 100/6/12.5 µg | Symbicort Turbuhaler 160/4.5 µg |
|---|---|---|
| Started | 353 | 355 |
| Itt population | 351 | 355 |
| Per protocol population | 314 | 317 |
| Safety population | 352 | 355 |
| Completed | 318 | 311 |
| Not completed | 35 | 44 |
| Withdrew: Withdrawal by subject | 15 | 21 |
| Withdrew: Protocol violation | 7 | 7 |
| Withdrew: Adverse event | 7 | 4 |
| Withdrew: Copd exacerbation | 1 | 6 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24 | 0.030 (0.013 to 0.046) | -0.032 (-0.049 to -0.015) |
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Change From Baseline in 2-hour Post-dose FEV1 at Week 24 | 0.185 (0.167 to 0.204) | 0.072 (0.053 to 0.091) |
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| week 4 (V3) | 0.067 (0.055 to 0.080) | 0.005 (-0.008 to 0.018) |
| week 12 (V4) | 0.055 (0.041 to 0.070) | -0.031 (-0.046 to -0.017) |
| week 18 (V5) | 0.046 (0.029 to 0.062) | -0.025 (-0.042 to -0.009) |
| week 24 (V6) | 0.030 (0.013 to 0.046) | -0.032 (-0.049 to -0.015) |
FEV1 measures the amount, or volume, exhaled by a patient in the first second of the expiration after a full inspiration. The lower the values, more severe the airflow limitation. For FEV1, the highest value from 3 technically acceptable attempts was recorded irrespective of the curve they were derived from. The chosen highest value had not to exceed the second highest by more than 150 mL; if the difference was larger, up to 8 measurements were performed and the largest value reported. Please note that the adjusted mean is reported with its 95%IC.
| liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| week 0 (V2) | 0.163 (0.152 to 0.175) | 0.063 (0.052 to 0.075) |
| week 4 (V3) | 0.203 (0.188 to 0.219) | 0.096 (0.080 to 0.111) |
| week 12 (V4) | 0.209 (0.192 to 0.226) | 0.039 (0.022 to 0.056) |
| week 18 (V5) | 0.206 (0.188 to 0.225) | 0.070 (0.052 to 0.089) |
| week 24 (V6) | 0.185 (0.167 to 0.204) | 0.072 (0.053 to 0.091) |
FEV1 response is defined as a change from baseline in pre-dose morning FEV1 ≥ 100 mL. If the change from baseline is \< 100 mL the patient is classified as a non-responder in terms of FEV1. Patients with missing pre-dose morning FEV1 value at the relevant time points were also be classified as non-responders. The number and percentage of FEV1 responders/non-responders (distinguishing also the two categories of non-responders: with a change from baseline actually \< 100 mL or with missing data) at Visit 6 are presented by treatment group.
| Participants | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Responders | 91 | 43 |
| Non responders due to Change < 100 mL | 224 | 263 |
| Non responders due to missing data | 36 | 49 |
The changes from pre-dose to the 2-hour post-dose morning FEV1 at each clinic visit from V3 onwards are presented by treatment in the ITT population. Please note that the adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 2-hour post-dose morning FEV1 | 0.137 (0.126 to 0.148) | 0.090 (0.079 to 0.101) |
| Week 12 2-hour post-dose morning FEV1 | 0.154 (0.142 to 0.166) | 0.074 (0.062 to 0.086) |
| Week 18 2-hour post-dose morning FEV1 | 0.164 (0.152 to 0.176) | 0.100 (0.087 to 0.112) |
| Week 24 2-hour post-dose morning FEV1 ( | 0.160 (0.148 to 0.172) | 0.109 (0.097 to 0.121) |
Moderate or Severe COPD exacerbations during the randomised treatment period derived from the COPD exacerbations (E) eCRF form were considered for the analysis. Only E with start date ≥ date of start of randomised treatment period and ≤ date of end of randomised treatment period were considered. Please note that in the analysis, two COPD E were considered as a single episode if the 2nd E started less than 10 days: * after the end of the systemic corticosteroids and/or antibiotics intake for the previous E; * after the onset of the previous E. In case of at least 1 E occurring before the randomisation and at least 1 E occurring after randomisation satisfied the rules above to be considered as single episode, then the resulting event was considered as occurring before the randomisation (i.e. it wasn't considered in the analyses of moderate or severe Es). Adjusted exacerbation rate per patient per year was reported (= number) with its 95% IC.
| events per patient per year | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Adjusted Rate Per Patient Per Year of Moderate or Severe COPD Exacerbations Over 24 Weeks of Treatment | 0.518 (0.409 to 0.565) | 0.908 (0.751 to 1.098) |
In patients with at least one moderate/severe COPD exacerbation, time to first moderate/severe COPD exacerbation was calculated as the time in weeks between the start date of randomised treatment period and the date at which the first COPD exacerbation occurs. Time to first moderate/severe COPD exacerbation (weeks) = (date of start of first moderate/severe COPD exacerbation - date of start of randomised treatment period)/7. Please note that the Rows don't represent mutually exclusive and exhaustive categories of the overall number of participants analyzed (N=351 for CHF 5993 and N=355 for Symbicort Turbuhaler). The number of exacerbation-free patients at the beginning of each study period is reported for each row (not the number of participants analyzed), with the relative cumulative number of patients with first moderate/severe exacerbation at the end of each study period (unit of measure).
| # of pts with event at end of period | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| 0-4 weeks: n. of exacerbation-free patients at the beginning of this study period | 351 | 355 |
| 0-4 weeks: n. of patients with first moderate/severe exacerbation at the end of this study period | 18 | 39 |
| 4-12 weeks: n. of exacerbation-free patients at the beginning of this study period | 325 | 310 |
| 4-12 weeks: n. of patients with first moderate/severe exacerbation at the end of this study period | 23 | 32 |
| 12-18 weeks: n. of exacerbation-free patients at the beginning of this study period | 296 | 267 |
| 12-18 weeks: n. of patients with first moderate/severe exacerbation at the end of this study period | 14 | 24 |
| 18-24 weeks: n. of exacerbation-free patients at the beginning of this study period | 274 | 241 |
| 18-24 weeks: n. of patients with first moderate/severe exacerbation at the end of this study period | 10 | 13 |
| 24 weeks - EoT: n. of exacerbation-free patients at the beginning of this study period | 87 | 81 |
| 24 weeks - EoT: n. of patients with first mod/sev exacerbation at the end of this study period | 1 | 1 |
| 0-24 weeks: n. of exacerbation-free patients at the beginning of this study period | 351 | 355 |
| 0-24 weeks: n. of patients with first moderate/severe exacerbation at the end of this study period | 66 | 109 |
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Baseline in Pre-Dose Morning Forced Vital Capacity (FVC) at all clinic visits are presented by treatment in the ITT population. Please note that adjusted mean was reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 | 0.140 (0.113 to 0.168) | 0.016 (-0.011 to 0.044) |
| Week 12 | 0.091 (0.059 to 0.122) | -0.067 (-0.098 to -0.036) |
| Week 18 | 0.067 (0.033 to 0.101) | -0.071 (-0.105 to -0.036) |
| Week 24 | 0.035 (-0.001 to 0.071) | -0.104 (-0.140 to -0.067) |
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Baseline in 2-hour post-dose Forced Vital Capacity (FVC) at all clinic visits are presented by treatment in the ITT population. Please note that adjusted mean is reported with its 95%IC.
| liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| week 0 | 0.344 (0.317 to 0.370) | 0.132 (0.106 to 0.159) |
| week 4 | 0.397 (0.364 to 0.430) | 0.207 (0.174 to 0.240) |
| week 12 | 0.387 (0.350 to 0.423) | 0.101 (0.065 to 0.137) |
| week 18 | 0.371 (0.332 to 0.410) | 0.146 (0.107 to 0.185) |
| week 24 | 0.327 (0.289 to 0.365) | 0.134 (0.096 to 0.172) |
FVC is defined as the total amount of air exhaled during the FEV test. Forced vital capacity, together with Forced Expiratory Volume, are lung function tests that are measured during spirometry. The lower the capacity, the worse the respiratory functionality. Change from Pre-Dose to the 2-Hour Post-Dose Value of Forced Vital Capacity (FVC) at all clinic visits from V3 onwards are presented by treatment in the ITT population. Please note that adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 | 0.258 (0.233 to 0.283) | 0.191 (0.166 to 0.215) |
| Week 12 | 0.297 (0.272 to 0.323) | 0.175 (0.150 to 0.200) |
| Week 18 | 0.308 (0.283 to 0.333) | 0.228 (0.203 to 0.253) |
| Week 24 | 0.299 (0.272 to 0.325) | 0.249 (0.222 to 0.275) |
The FEV1/FVC ratio, also called modified Tiffeneau-Pinelli index, is a calculated ratio used in the diagnosis of obstructive and restrictive lung disease. The FEV1/FVC ratio is used to determine if the pattern is obstructive, restrictive, or normal. Chronic airflow limitation can be generally defined as fixed ratio of forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) \< 0.70 after bronchodilation. So the lower the value, the worse the outcome and the pattern. Pre-dose FEV1/FVC at each visit was summarised by treatment group using descriptive statistics.
| ratio | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Baseline | 41.2 ± 9.2 | 40.1 ± 8.4 |
| Week 0 | 41.2 ± 9.2 | 40.1 ± 8.4 |
| Week 4 | 41.6 ± 9.3 | 40.3 ± 8.7 |
| Week 12 | 42.0 ± 8.9 | 40.3 ± 8.8 |
| Week 18 | 41.9 ± 8.8 | 40.4 ± 8.5 |
| Week 24 | 41.7 ± 8.9 | 40.8 ± 8.6 |
FEF25-75% is defined as "forced expiratory flow over the middle one-half of the FVC; the average flow from the point at which 25% of the FVC has been exhaled to the point at which 75% of the FVC has been exhaled." A reduced FEF25-75% is thought to be a marker of small airway obstruction. Hence, the lower the parameter, the worse the status of airways. Among the various measurements collected during conventional spirometry, forced expiratory flow at 25% and 75% of the pulmonary volume (FEF25-75) measures the average flow rates of medium-to-small airways during the forced vital capacity (FVC) segment to testing and presents the status of those airways in patients. The changes from baseline in pre-dose morning FEF25-75% at baseline and at all subsequent clinic visits are presented by treatment in the ITT population. Please note: adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 | 0.024 (0.017 to 0.031) | 0.004 (-0.003 to 0.011) |
| Week 12 | 0.023 (0.015 to 0.031) | -0.009 (-0.017 to -0.001) |
| Week 18 | 0.023 (0.013 to 0.032) | -0.000 (-0.010 to 0.009) |
| Week 24 | 0.018 (0.009 to 0.028) | 0.001 (-0.009 to 0.011) |
IC is the maximum volume of air that can be inspired following a normal, quiet expiration and is equal to tidal volume + inspiratory reserve volume. In airflow obstruction, hyperinflation of the lung and chest wall during tidal breathing (and during exercise) increases the work of breathing and contributes to the sensation of dyspnoea. The lower the volume, the worse the outcome and, consequently, the impairment. Please note that adjusted mean is reported with its 95%IC.
| Liters | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 | 0.074 (0.042 to 0.107) | 0.023 (-0.008 to 0.055) |
| Week 12 | 0.065 (0.032 to 0.099) | -0.011 (-0.045 to 0.023) |
| Week 18 | 0.053 (0.018 to 0.088) | -0.012 (-0.047 to 0.023) |
| Week 24 | 0.086 (0.047 to 0.125) | -0.027 (-0.067 to 0.012) |
The SGRQ measures health impairment in patients with COPD. It is in two parts: Part I produces the Symptoms score, Part 2 the Activity and Impacts scores. Scaling of items * Section I (Symptoms): 5-point Likert * Sections II (Activity) and III (Impacts): Dichotomous (yes/no) Total score=(Summed weights from positive items in the SGRQ / Sum of weights for all items in the SGRQ) x 100. Lower the scores, better the health. Each item is "weighted" empirically. Scores range from 0 to 100, higher scores mean poor health. Part 1(Q 1-8) covers the patients' recollection of their symptoms over a preceding period that may range 1 month to 1 year. Part 2 (Q 9-16) addresses patients' current state. Activity score just measures disturbances to patients daily physical activity. Impacts score covers a wide range of disturbances of psycho-social function. Please note: adjusted mean is reported with its 95%IC.
| score on a scale | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 12 | -3.69 (-5.09 to -2.28) | -0.41 (-1.81 to 0.99) |
| Week 24 | -3.40 (-4.91 to -1.89) | -0.33 (-1.84 to 1.18) |
The percentage of patients classified as SGRQ total score responders (i.e. change from baseline in total score ≤ -4) at Week 24 was reported. SGRQ response = Change from baseline in total score ≤ -4; SGRQ non-response = Change from baseline in total score \> -4 or missing data.
| Participants | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Responders | 149 | 119 |
| Non responders due to change > -4 | 164 | 191 |
| Non responders due to missing data | 38 | 45 |
The COPD assessment test (CAT) is a self-administered questionnaire assessing globally the impact of COPD (cough, sputum, dysnea, chest tighteness) on health status. It's a simple, eight-item/question, health status instrument for patients with COPD to define the level of its impact on daily life. Each item can score from 0 (best outcome) to 5 (worst outcome). Hence, CAT total score, which is the sum of the single items' scores, ranges from 0 to 40. Higher scores denote a more severe impact of COPD on a patient's life. No target score represents the best achievable outcome. Please note that adjusted mean is reported with its 95%IC.
| score on a scale | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Week 4 | -1.544 (-2.039 to -1.050) | -0.848 (-1.342 to -0.354) |
| Week 12 | -1.483 (-2.035 to -0.930) | -0.211 (-0.762 to 0.340) |
| Week 18 | -1.154 (-1.738 to -0.570) | -0.326 (-0.914 to 0.263) |
| Week 24 | -1.008 (-1.615 to -0.401) | 0.226 (-0.386 to 0.838) |
The percentage (%) of days without intake of rescue medications was evaluated on the basis of the infos recorded daily by each patient. The % of days in the run-in period was calculated as follows: % of days without rescue medication = (Number of days without rescue medication during the run-in period / Number of days with consistent data recorded during this period)\*100. The % of days in each inter-visit period during the randomised treatment period was calculated as follows: • % of days without rescue medication = (Number of days without rescue medication during the inter-visit period / Number of days with consistent data recorded during this period)\*100. The % of days in the entire randomised treatment period was calculated as follows: • % of days without rescue medication = (Number of days without rescue medication during the randomised treatment period / Number of days with consistent data recorded during this period)\*100.
| percentage of days | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| V2-V3 | 9.258 ± 27.930 | 0.620 ± 27.863 |
| V3-V4 | 10.683 ± 29.928 | 3.314 ± 33.560 |
| V4-V5 | 10.941 ± 30.538 | 2.283 ± 33.474 |
| V5-V6 | 10.263 ± 30.344 | 3.182 ± 33.951 |
| Weeks 1-24 (overall randomised treatment period) | 10.500 ± 27.515 | 2.554 ± 29.588 |
The average use of rescue medication is expressed in "puffs/day". Data on each interval indicated in the timeframe and over the 24-week of the randomised treatment period is presented.
| puffs/day | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| V2-V3 | -0.286 ± 1.154 | -0.098 ± 0.948 |
| V3-V4 | -0.307 ± 1.220 | -0.183 ± 1.068 |
| V4-V5 | -0.331 ± 1.086 | -0.158 ± 1.135 |
| V5-V6 | -0.318 ± 1.087 | -0.197 ± 1.112 |
| Weeks 1-24 (whole randomised treatment period) | -0.336 ± 1.171 | -0.150 ± 1.019 |
The EQ-5D-3L (euro quality of life) consists of the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system comprises 5 dimensions: * mobility * self-care * usual activities * pain/discomfort * anxiety /depression. Each dimension has 3 levels: no problems, some problems, extreme problems. A unique health state is defined by combining 1 level from each of the 5 dimensions. There are 243 possible health states/sequences defined in this way. Each state is referred to in terms of a 5-digit code (for example 11223). The 243 theoretical possible sequences can then be mapped to an index value to provide a summary across all dimensions. For the calculation of the index value, the Time Trade-Off method was used. The index can range from 1 (full health) to 0 (worst health).
| index (decimal number) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| V2 | 0.778 ± 0.203 | 0.790 ± 0.185 |
| V4 | 0.804 ± 0.185 | 0.794 ± 0.192 |
| V6 | 0.802 ± 0.193 | 0.788 ± 0.206 |
The EQ-5D-3L (euro quality of life) consists of the EQ-5D descriptive system and the EQ VAS. The EQ VAS records the patient's self-rated health on a vertical, visual analogue scale where the endpoints are 'Worst imaginable health state' (0) and 'Best imaginable health state' (100).
| score on a scale | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| V2 | 70.9 ± 14.7 | 70.4 ± 14.9 |
| V4 | 74.0 ± 13.5 | 69.4 ± 16.0 |
| V6 | 73.5 ± 13.8 | 71.0 ± 14.5 |
This health-economic outcome is expressed by the number of Hospital Admissions due to COPD and to Other Causes overall.
| no of admission | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| N. due to COPD | 19 | 35 |
| N. due to other causes | 19 | 22 |
This health-economic outcome is expressed by the number of oxygen therapy use due to COPD.
| no of oxygen therapy | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Total Number of Oxygen Therapy Use Due to COPD | 28 | 47 |
This health-economic outcome is expressed by the number of Diagnostic or Instrumental tests performed due to COPD.
| no of tests | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population |
|---|---|---|
| Total Number of Unplanned Diagnostic or Instrumental Tests Performed Due to COPD | 3 | 5 |
AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.
| number of events | CHF 5993 100/6/12.5 µg - Safety Population | Symbicort Turbuhaler 160/4.5 µg - Safety Population |
|---|---|---|
| AEs | 496 | 599 |
| SAEs | 51 | 76 |
| ADRs | 10 | 24 |
| serious ADRs | 1 | 0 |
| severe AEs | 46 | 75 |
| AEs Leading to Discontinuation from Study Medication | 10 | 17 |
| AEs Leading to Death | 1 | 5 |
Collected over Throughout the study from screening (V1, week -2), during the whole treatment period (V2-V5) till the End of Study (V6, at week 24 or at earlier patient withdrawal). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF 5993 100/6/12.5 µg - Safety Population | 1/352 (0.3%) | 40/352 (11.4%) | 215/352 (61.1%) |
| Symbicort Turbuhaler 160/4.5 µg - Safety Population | 3/355 (0.8%) | 60/355 (16.9%) | 238/355 (67%) |
| Event | CHF 5993 100/6/12.5 µg - Safety Population | Symbicort Turbuhaler 160/4.5 µg - Safety Population |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 20/352 | 43/355 |
| PneumoniaInfections and infestations | 4/352 | 9/355 |
| InfluenzaInfections and infestations | 2/352 | 0/355 |
| Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders | 2/352 | 0/355 |
| Angina pectorisCardiac disorders | 1/352 | 0/355 |
| Cardiac failureCardiac disorders | 1/352 | 1/355 |
| Ventricular extrasystolesCardiac disorders | 1/352 | 0/355 |
| Abdominal painGastrointestinal disorders | 1/352 | 0/355 |
| Intestinal obstructionGastrointestinal disorders | 1/352 | 0/355 |
| Large intestine polypGastrointestinal disorders | 1/352 | 0/355 |
| Event | CHF 5993 100/6/12.5 µg - Safety Population | Symbicort Turbuhaler 160/4.5 µg - Safety Population |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 66/352 | 110/355 |
| Upper respiratory tract infectionInfections and infestations | 58/352 | 49/355 |
| HypertensionVascular disorders | 12/352 | 24/355 |
| NasopharyngitisInfections and infestations | 22/352 | 23/355 |
| PneumoniaInfections and infestations | 8/352 | 13/355 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 9/352 | 9/355 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/352 | 8/355 |
| Back painMusculoskeletal and connective tissue disorders | 0/352 | 8/355 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/352 | 8/355 |
| HypokalaemiaMetabolism and nutrition disorders | 0/352 | 7/355 |
Intention-to-treat (ITT) Population: All unique randomised patients who received at least one administration of the study treatment and with at least one available evaluation of efficacy after baseline. If a patient was unintentionally randomised twice in the study, only the data collected from the initial randomisation site were considered for analysis.
| Age, Categorical(Participants) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 146 | 159 | 305 |
| >=65 years | 205 | 196 | 401 |
| Age, Continuous(years) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population | Total |
|---|---|---|---|
| Mean | 66.0 ± 7.1 | 65.9 ± 7.7 | 65.9 ± 7.4 |
| Sex: Female, Male(Participants) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population | Total |
|---|---|---|---|
| Female | 15 | 18 | 33 |
| Male | 336 | 337 | 673 |
| Race/Ethnicity, Customized(Participants) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population | Total |
|---|---|---|---|
| Asian | 351 | 355 | 706 |
| Region of Enrollment(participants) | CHF 5993 100/6/12.5 µg - ITT Population | Symbicort Turbuhaler 160/4.5 µg - ITT Population | Total |
|---|---|---|---|
| South Korea | 54 | 54 | 108 |
| China | 286 | 290 | 576 |
| Taiwan | 11 | 11 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.
Ran from Dec 2016 to primary completion in May 2020, 41 months.
Results were first posted in May 2026, 6 years after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 41 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →